Clinical trials: Platelet Aggregation Inhibitors
Chronic Kidney Disease
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Higher coronary in-stent thromboses and bleeding complications on anti-platelet agents are more common in Chronic Kidney Disease vs. non-Chronic Kidney Disease patients.
- Trial name
- WiCKDonASA (NCT01768637)
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cardiovascular Diseases, Acute Coronary Syndrome
Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence
This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers.
- Trial name
- NCT05474053
- Testing
- Ticagrelor 90mg (Brilique), Ticagrelor 90mg (Ticaloguard)
- Where
- Egypt
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cairo University
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 (Bentracimab) with and without…
- Trial name
- NCT05162131
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Drug Safety
Data-driven Quality Improvement in Primary Care - Trial
A cluster randomised controlled trial to test the effectiveness of an informatics tool, educational and financial incentives to reduce high risk prescribing of non-steroidal anti-inflammatory drugs and anti-platelet agents.
- Trial name
- DQIP (NCT01425502)
- Testing
- DQIP Intervention
- Where
- 2 sites in United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Drug Interaction Potentiation, Myocardial Infarction
Drug Drug Interactions of Aspirin and P2Y12-inhibitors
Study Objective: To investigate potential drug-drug interactions (pharmacokinetics and pharmacodynamics) of morphine and antiplatelet drugs (aspirin, clopidogrel, prasugrel, ticagrelor)
- Trial name
- NCT01369186
- Testing
- Morphine
- Where
- Austria
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Gastroduodenal Ulcer
Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers
Gastroduodenal ulcers are extremely common in the community today. Though much has been written and observed concerning how ulcers form, not much has been described in the human model concerning how these ulcers heal.
- Trial name
- Lesions2 (NCT00778193)
- Testing
- Naproxen, Aspirin, Celecoxib
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Research Associates of New York, LLP
Acute Coronary Syndome
Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?
Background Acute coronary syndrome (ACS) is a term representing all diseases related to reduction in blood flow to the heart characterised by clot formation over a segment of blood vessel narrowing.
- Trial name
- PLATE NOX (NCT02169596)
- Testing
- Ticagrelor, EndoPAT - endothelial assessment
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Platelet Aggregation Inhibitors, Aspirin
GM03 - Platelet RNA Signatures of Aspirin
This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into…
- Conditions
- Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
- Trial name
- NCT05278637
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Duke University
30 Healthy People
Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay
Currently, drugs commonly used for antiplatelet are aspirin and clopidogrel when encountering stroke or coronary heart disease. In this study, we would use VASP assay and thromboelastograph with platelet mapping assay kit to…
- Trial name
- NCT01023360
- Testing
- Clopidogrel and proton pump inhibitors
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Platelet Thrombus
Characterization of Exosomes Platelets-released
Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics.
- Trial name
- EXOPLT (NCT06298682)
- Where
- Italy
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Centro Cardiologico Monzino
Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry
The purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy…
- Trial name
- NCT04822363
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Gender, Sex
Sexual Hormones and Haemostasis: Observations for Women Health
Atherothrombotic disorders account for 25% of all deaths among women and for substantial morbidity and resource use in health care.
- Trial name
- SHOW (NCT02055001)
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Bioequivalence
Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition
To compare the rate and extent of absorption of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® (clopidogrel) 75 mg tablet under fasting condition.
- Trial name
- NCT05186129
- Testing
- Clopid® 75 mg Tablet, Plavix® 75mg Tablet
- Where
- Pakistan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Center for Bioequivalence Studies and Clinical Research
Platelet Aggregation Inhibitors
Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin
ASA inhalation powder is an inhaled nonsteroidal anti-inflammatory drug-device combination that has been developed to reduce the risk of vascular mortality in patients with suspected acute myocardial infarction (MI), an FDA…
- Trial name
- NCT04328883
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Inova Health Care Services
Healthy
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
The primary objective of this study is to investigate the effects of Cilostazol, Acetylsalycylic acid and Clopidogrel alone as well as combinations of Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo…
- Trial name
- CiloMecT (NCT02554721)
- Testing
- Cilostazol, Acetylsalicylic acid, Clopidogrel
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects
To test pharmacodynamic response to clopidogrel 150mg once daily during 7 days in healthy subjects carriers of a mutated allele (*2) associated with CYP2C19 deficiency and non responders to the usual regimen of 75 mg once daily
- Trial name
- NCT00413608
- Testing
- Clopidogrel
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myocardial Infarction
Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation.
- Trial name
- AFFECT EV (NCT02931045)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Platelet Function and Reactivity Tests
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
- Trial name
- NCT06933056
- Testing
- Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Sickle Cell Disease
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall…
- Trial name
- NCT03126695
- Testing
- Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca